Role of Saxenda (Liraglutide) in Weight Loss Management

Introduction to Liraglutide

• The American Diabetes Association recommends Saxenda (liraglutide 3.0 mg) as an effective FDA-approved medication for chronic weight management in patients with obesity, producing 5.8-8.0% weight loss when used as an adjunct to lifestyle modifications 1, 2

Mechanism of Action

• Liraglutide is a GLP-1 receptor agonist with 97% homology to human GLP-1, a gut-derived incretin hormone 3

FDA Approval and Dosing

• The FDA approved liraglutide in 2014 specifically for chronic weight management in patients with obesity 3, 4
• Liraglutide is indicated for patients with a BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity (such as hypertension, dyslipidemia, or type 2 diabetes) 5, 4
• The dosing protocol for liraglutide starts at 0.6 mg daily for 1 week and increases by 0.6 mg weekly until reaching the target dose of 3.0 mg 3, 4

Clinical Efficacy

• The American Journal of Respiratory and Critical Care Medicine reports that liraglutide demonstrated decreased neck circumference (mean difference -0.8 cm) 2
• The American Journal of Respiratory and Critical Care Medicine also reports that liraglutide improved AHI (mean difference -6.1 events/h) 5, 6
• Weight loss with liraglutide correlates with improvements in metabolic parameters, including improved insulin resistance 2

Side Effects and Safety Considerations

• The most common adverse effects of liraglutide are gastrointestinal, including nausea 3 and vomiting 2
• Other potential side effects include headache 3 and hypoglycemia (particularly in patients with diabetes) 1
• Serious safety concerns include potential risk of pancreatitis 2 and thyroid C-cell tumors in rodents (contraindicated in patients with personal/family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2) 1, 7

Comparison to Newer GLP-1 Receptor Agonists

• More recent GLP-1 receptor agonists have shown greater efficacy, with semaglutide 2.4 mg weekly producing mean weight loss of 14.9-16.0% at 68 weeks 2
• Tirzepatide (dual GIP/GLP-1 receptor agonist) produces mean weight loss of 15.0-20.9% at 72 weeks 2

Practical Considerations

• Liraglutide should be used as an adjunct to comprehensive lifestyle modifications including diet and exercise 5
• Patients should be monitored for weight loss response (discontinue if <4% weight loss after 16 weeks) 4
• The average wholesale price of liraglutide is approximately $1,385 per month for the maintenance dose 1